GlassScriptPhysician profile
Kathryn E Albert
NPI 1356754618
$5,416.88
in general payments reported to CMS, 2019-2025
27 companies · $895 in 2025
The $895 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,158 · 2022: $1,237 · 2023: $1,082 · 2024: $1,044 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,960 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.86 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,385.17 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,001.80 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $468.28 | 2021-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $388.26 | 2022-2025 | Taltz, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $361.53 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $250.36 | 2021-2025 | Trintellix |
| Astellas Pharma US INC | $202.53 | 2021-2023 | Myrbetriq |
| Sanofi-Aventis U.S. LLC | $142.00 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $137.04 | 2021-2022 | |
| Novo Nordisk INC | $124.91 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $111.75 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $110.58 | 2024-2025 | Zenpep |
| Teva Pharmaceuticals USA, INC. | $103.34 | 2022-2023 | Austedo |
| Novartis Pharmaceuticals Corporation | $100.48 | 2024-2025 | |
| Pfizer INC. | $83.82 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $73.42 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $67.89 | 2021-2024 | Camzyos |
| Biohaven Pharmaceuticals, INC. | $58.19 | 2021 | |
| Antares Pharma, INC. | $51.58 | 2021-2022 | |
| Lundbeck LLC | $43.43 | 2022-2024 | Rexulti |
| Amarin Pharma, INC. | $34.23 | 2021 | |
| Eisai INC. | $29.68 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.08 | 2022 | |
| Esperion Therapeutics, INC. | $18.57 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.27 | 2022 | |
| Halozyme INC | $17.44 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.